US5635186A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof
Assignee: Sky High LLC
•
Filing: 1995-05-30
•
Granted: 1997-06-03
•
Expires: 2015-05-30
Abstract
Abstract The present invention is to methods of obtaining plant-derived compositions that inhibit apoptosis, the compositions obtained thereby, compositions comprising the composition, and methods of use thereof.
Inventors
- 👤 Ian C. Bathurst
- 👤 John D. Bradley
- 👤 L. David Tomei
- 👤 Philip J. Barr
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 17:36
CPC Classifications
A; A61; A61K; A61K36/00; A61K36/18; A61K36/185; A61K36/48; A61K35/00; A61K35/12; A61K35/20; A61K8/00; A61K8/18; A61K8/96; A61K8/97; A61K8/9783; A61K8/9789; A61K8/9794; A61P; A61P1/00; A61P1/04; A61P17/00; A61P25/00; A61P25/28; A61P31/00; A61P31/12; A61P31/14; A61P31/18; A61P37/00; A61P39/00; A61P43/00; A61P9/00; A61Q; A61Q19/00; A61Q19/08
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
95 words
A method of treatment of apoptosis, comprising administering a therapeutically effective amount of a pharmaceutically acceptable composition comprising the composition comprising a factor with anti-apoptotic activity wherein the method comprises the steps of: a) delipidating a plant powder with a delipidating agent; b) separating the powder from the delipidating agent; c) extracting the delipidated powder with an aqueous solution; d) separating the aqueous solution from the delipidated powder to obtain an aqueous retentate; and e) isolating a lipid/glycolipid/phospholipid fraction containing the factor wherein the composition is administered to a patient in need of such treatment.
Claim 2
Independent Claim
95 words
A method of treatment of apoptosis, comprising administering a therapeutically effective amount of a pharmaceutically acceptable composition comprising the composition comprising a factor with anti-apoptotic activity wherein the method comprises the steps of: a) delipidating a plant powder with a delipidating agent; b) separating the powder from the delipidating agent; c) extracting the delipidated powder with an aqueous solution; d) separating the aqueous solution from the delipidated powder to obtain an aqueous retentate; and e) isolating a lipid/glycolipid/phospholipid fraction containing the factor wherein the composition is administered to a patient in need of such treatment.
Claim 3
Dependent Claim
15 words
The method according to claim 1 wherein the patient is suffering from a gastrointestinal perturbation.
Claim 4
Dependent Claim
28 words
The method according to claim 2 wherein the gastrointestinal perturbation is caused by a stimulus selected from the group consisting of human immunodeficiency virus, chemotherapeutic agents and radiation.
Claim 5
Dependent Claim
19 words
The method according to claim 2 wherein the treatment decreases immunodeficiencies associated with immunosuppressing viruses, chemotherapeutic agents, or radiation.
Claim 6
Dependent Claim
13 words
The method according to claim 4 wherein the virus is human immunodeficiency virus.
Claim 7
Dependent Claim
18 words
The method according to claim 5 wherein the treatment diminishes human immunodeficiency virus-associated apoptotic death of T cells.
Claim 8
Dependent Claim
15 words
The method according to claim 1 wherein the patient is undergoing apoptosis related to reperfusion.
Claim 9
Dependent Claim
25 words
The method according to claim 7 wherein the reperfusion is associated with coronary artery obstruction; cerebral infarction; spinal/head trauma and concomitant severe paralysis; and frostbite.
References Cited (Backward Citations)
US4340586A
Cited
US4263286A
Cited
US4959353A
Cited
US4793996A
Cited
US4818540A
Cited
US4695590A
Cited
JPS6351335A
Cited
US4746652A
Cited
US4959310A
Cited
WO1990003574A1
Cited
US5053327A
Cited
US5140043A
Cited
US5130298A
Cited
US5093505A
Cited
US5340568A
Cited
WO1994020121A1
Cited
US5326690A
Cited
WO1994025621A1
Cited
US5330972A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-06-02 | 2000-12-02 | 2001-06-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-06-02 | 2004-12-02 | 2005-06-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-06-02 | 2008-12-02 | 2009-06-03 | $7700.00 | Window Closed / Lapsed |